30
Participants
Start Date
November 3, 2021
Primary Completion Date
October 20, 2022
Study Completion Date
October 20, 2022
SM08502
SM08502 to be administered orally.
Abiraterone
Abiraterone to be administered orally.
Prednisone
Prednisone to be administered orally.
Docetaxel
Docetaxel to be administered intravenously.
FOLFIRI Protocol
FOLFIRI Protocol to be administered intravenously.
Panitumumab
Panitumumab to be administered intravenously.
Saint Vincent's Hospital, Darlinghurst
Chris O'Brien Lifehouse, Camperdown
Icon Cancer Care-South Brisbane, South Brisbane
The Queen Elizabeth Hospital (TQEH), Woodville South
Virginia Cancer Specialists, PC, Fairfax
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke
Vanderbilt University, Nashville
The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, LLC, Cincinnati
START Midwest, Grand Rapids
Texas Oncology, Fort Worth
Texas Oncology-San Antonio Northeast, San Antonio
UT Health San Antonio - Mays Cancer Center - Institute for Drug Development, San Antonio
University of Colorado, Aurora
START Mountain Region, West Valley City
The University of Arizona Cancer Center (UACC) - North Campus, Tucson
University of Colorado, Anschutz, Aurora
Maine Center for Cancer Medicine, Scarborough
Memorial Sloan-Kettering Cancer Center, New York
Duke Cancer Institute (DCI) - Duke Cancer Center, Durham
Seattle Cancer Care Alliance (SCCA), Seattle
Lead Sponsor
Biosplice Therapeutics, Inc.
INDUSTRY